Segment Information (Tables)

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment is as follows:

	Year Ended December 31, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	—		$	5,441	$	17,330		$	—			$	22,771
Gross profit		—			3,791		2,964			—				6,755
Direct expenses		28,694			1,752		9,720			40,876				81,041
Segment contribution		(28,694	)		2,039		(6,756	)		(40,876	)			(74,286	)
Indirect expenses										118,001		(a)		118,001
Loss from operations													$	(192,287	)
(a) Components of other
Change in fair value of contingent consideration liability										(104,339	)
Goodwill impairment										112,347
IPR&D impairment										107,800
Amortization										2,193
Total other									$	118,001

	Year Ended December 31, 2022
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	—		$	5,512	$	12,463		$	—			$	17,975
Gross profit		—			1,976		(3,666	)		—				(1,690	)
Direct expenses		75,379			1,699		10,859			56,261				144,198
Segment contribution		(75,379	)		277		(14,525	)		(56,261	)			(145,888	)
Indirect expenses										(120,288	)	(b)		(120,288	)
Loss from operations													$	(25,600	)
(b) Components of other
Change in fair value of contingent consideration liability										(126,277	)
Change in fair value of contingent stock consideration										186
Goodwill impairment										3,610
Amortization										2,193
Total other									$	(120,288	)